Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...

Educational achievement gaps persist globally, with some ethnic minority and socioeconomically disadvantaged students consistently underperforming. Self-affirmation interventions, brief ...

CISOs Say a Cyberattack Is Inevitable. 75% Admit They're Missing Key Evidence When It Happens. What If the AI Agent Destroyed ...